SpyBiotech: protein superglue for plug-and-display vaccine development

SpyBiotech is developing a protein superglue technology to improve the speed and simplicity of manufacturing vaccines with a “plug-and-display” capability across different delivery platforms. A deal with the Serum Institute of India is providing an early opportunity to generate human proof of concept for a COVID-19 vaccine.

The Oxford-based biotech will use the $32.5 million in proceeds from its series A round announced Wednesday to advance an internal program targeting cytomegalovirus (CMV) into the clinic, and to build out the platform to position it to rapidly respond to current and future pandemic scenarios...